TY - JOUR
T1 - Antibacterial Activity of DC-159a Against Salmonella Typhimurium
AU - Koide, Kentaro
AU - Kongsoi, Siriporn
AU - Ouchi, Yuki
AU - Yamaguchi, Tomoyuki
AU - Nakajima, Chie
AU - Suzuki, Yasuhiko
N1 - Funding Information:
This work was supported in part by a grant from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, for the Joint Research Program of the Research Center for Zoonosis Control, Hokkaido University to Y.S., and in part by the Japan Initiative for Global Research Network on Infectious Diseases, Grant No. 15fm0108008h0001 from the Japan Agency for Medical Research and Development (AMED) to Y.S. We are also grateful to Daiichi-Sankyo Co., Ltd. for providing DC-159a.
Publisher Copyright:
© Copyright 2019, Mary Ann Liebert, Inc., publishers 2019.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Quinolones show excellent antibacterial activity against Salmonella isolates. Recently, however, quinolone resistance has been increasing in bacteria. This study aimed to examine in vitro, and compare the activity of DC-159a against Salmonella enterica serovar Typhimurium with that of ciprofloxacin and nalidixic acid. Inhibitory effects of quinolones were assessed by the drug concentration needed to inhibit the supercoiling activity of recombinant DNA gyrases by 50% (IC 50 ). Dilution methods were used to determine the minimum inhibitory concentration (MIC) of quinolones against two different strains, Salmonella Typhimurium and Salmonella Enteritidis. The IC 50 s of DC-159a against mutant DNA gyrases were much lower than those of nalidixic acid and ciprofloxacin. In particular, the IC 50 of DC-159a against DNA gyrase with double mutation was less than 1/50 that of ciprofloxacin and nalidixic acid. MICs of DC-159a were higher than those of ciprofloxacin but lower than those of nalidixic acid. However, the estimated MICs of DC-159a against Salmonella strains with mutant DNA gyrase were lower than those of ciprofloxacin and nalidixic acid. Therefore, DC-159a can be suggested as an antibiotic candidate for treating salmonellosis caused by quinolone-resistant S. Typhimurium.
AB - Quinolones show excellent antibacterial activity against Salmonella isolates. Recently, however, quinolone resistance has been increasing in bacteria. This study aimed to examine in vitro, and compare the activity of DC-159a against Salmonella enterica serovar Typhimurium with that of ciprofloxacin and nalidixic acid. Inhibitory effects of quinolones were assessed by the drug concentration needed to inhibit the supercoiling activity of recombinant DNA gyrases by 50% (IC 50 ). Dilution methods were used to determine the minimum inhibitory concentration (MIC) of quinolones against two different strains, Salmonella Typhimurium and Salmonella Enteritidis. The IC 50 s of DC-159a against mutant DNA gyrases were much lower than those of nalidixic acid and ciprofloxacin. In particular, the IC 50 of DC-159a against DNA gyrase with double mutation was less than 1/50 that of ciprofloxacin and nalidixic acid. MICs of DC-159a were higher than those of ciprofloxacin but lower than those of nalidixic acid. However, the estimated MICs of DC-159a against Salmonella strains with mutant DNA gyrase were lower than those of ciprofloxacin and nalidixic acid. Therefore, DC-159a can be suggested as an antibiotic candidate for treating salmonellosis caused by quinolone-resistant S. Typhimurium.
KW - antimicrobial resistance
KW - fluoroquinolone
KW - nontyphoidal Salmonella
KW - Salmonella Typhimurium
UR - http://www.scopus.com/inward/record.url?scp=85059795423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059795423&partnerID=8YFLogxK
U2 - 10.1089/mdr.2018.0078
DO - 10.1089/mdr.2018.0078
M3 - Article
C2 - 30036136
AN - SCOPUS:85059795423
SN - 1076-6294
VL - 25
SP - 14
EP - 22
JO - Microbial Drug Resistance
JF - Microbial Drug Resistance
IS - 1
ER -